Melanoma Clinical Trials

Showing 281-300 of 1,145 trials

Clinical Study of CMP-001 in Combination With Pembrolizumab or as a Monotherapy

NCT02680184

This study will be conducted in two parts: Part 1 will be conducted using a Dose Escalation and Expansion design. The Part 1 Dose Escalation Phase of this study will identify a safe and tolerable dose to be further evaluated in the Part 1 Dose Expansion phase. Part 2 of the study will be conducted in parallel with the Part 1 Dose Expansion Phase and will evaluate the safety and efficacy of CMP-001 when administered as a monotherapy. A Treatment Extension to assess the safety profile of CMP-001 when given in combination with pembrolizumab or as monotherapy will be available to those who are currently being treated in either Part 1 or Part 2 of this study at the time of protocol Amendment 9, v10.0.

Melanoma

Regeneron Pharmaceuticals199 participantsStarted Apr 2016

Phoenix, Arizona, United States • Tucson, Arizona, United States • Duarte, California, United States +10 more locations

Active Not RecruitingPhase 2

Microbiota Transplant to Cancer Patients Who Have Failed Immunotherapy Using Faeces From Clinical Responders

NCT05286294

This is a single-arm, single-center, open-label, phase IIa study evaluating the safety, feasibility and efficacy of Faecal Microbiota Transplant (FMT) to cancer patients not responding to ICI therapy, using ICI-responders as donors.

Melanoma Stage IVHead and Neck Squamous Cell CarcinomaCutaneous Squamous Cell Carcinoma+3 more

Oslo University Hospital20 participantsStarted Jun 2022

Oslo, Norway

Clinical Study of CMP-001 in Combination With Pembrolizumab or as a Monotherapy

Microbiota Transplant to Cancer Patients Who Have Failed Immunotherapy Using Faeces From Clinical Responders

Related Searches

Adoptive Cell Transfer of Autologous Tumor Infiltrating Lymphocytes and High-Dose Interleukin 2 in Select Solid Tumors

Dendritic Cells (White Blood Cells) Vaccination for Advanced Melanoma

Symptom Management for YA Cancer Survivors

FAPi Radioligand OpeN-Label, Phase 1 Study to Evaluate Safety, Tolerability and DosImetry of [Lu-177]-PNT6555; A Dose Escalation Study for TReatment of Patients With Select Solid Tumors (FRONTIER)

APA (Adapted Physical Activity) for Patients With Advanced Melanoma

Sentinel Lymph Node Biopsy for Cutaneous Squamous Cell Carcinoma of the Head and Neck

Nemvaleukin Alfa Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Cutaneous or Mucosal Melanoma - ARTISTRY-6

Study Comparing the Standard Administration of IO Versus the Same IO Administered Each 3 Months in Patients in Response After 6 Months of Standard IO

Efficacy & Safety for LN144 With Pembrolizumab With High Risk Stage IIIb-dResectable Melanoma

Exercise to Boost Response to Checkpoint Blockade Immunotherapy

Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies

Expanded Access to Omaveloxolone for Melanoma for Patients Previously Enrolled in 408-C-1401

Study of Two Dose Levels of RTA 402 in Patients With Advanced Malignant Melanoma

Evaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ Tumors

Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC

A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors

Adjuvant Melatonin for Uveal Melanoma

Sitravatinib and Tislelizumab in Patients With Metastatic Uveal Melanoma With Liver Metastases.